New 'Tri-Specific' antibody takes aim at Hard-to-Treat cancers

NCT ID NCT07055594

Recruiting now Disease control Sponsor: Shine-On Biomedical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new drug called SOA101, a special antibody that can attach to both cancer cells and immune cells to help the immune system attack tumors. It is for people with advanced solid tumors (like lung, ovarian, or breast cancer) who have no other standard treatment options. The trial has two phases: first, finding the safest dose, and then checking if the drug shrinks tumors. About 76 participants will take part.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SOA101 (a trispecific antibody that targets cancer cells and immune cells)
What this could lead to: If successful, this could lead to a new treatment option for people with advanced solid tumors who have run out of standard therapies.
What could go wrong: This is an early-phase trial with a small number of participants, so the drug may not prove effective or safe enough for wider use. Side effects from immune activation are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer colorectal cancer head and neck carcinoma non-small cell lung carcinoma ovarian cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOLID TUMORS

Contacts and locations

Locations

China Medical University Hospital
RECRUITING

Taichung, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.